Literature DB >> 26489426

Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei).

P Barrios1,2, F Losa3, S Gonzalez-Moreno4, A Rojo4, A Gómez-Portilla5, P Bretcha-Boix6, I Ramos3, J Torres-Melero7, R Salazar8, M Benavides9, T Massuti10, E Aranda11,12.   

Abstract

The epithelial appendiceal neoplasms are uncommon and are usually detected as an unexpected surgical finding. The general surgeon should be aware of the diversity of its clinical manifestations and biological behaviors along with the significance of the surgical treatment on the progression of the illness and the prognosis of the patients. The operative findings and, especially, tumor histology, determine the type of surgery. Intestinal histologic subtype behaves and should be treated similarly to the right colon neoplasms; while mucinous tumors, often discordant between histology and its aggressiveness, can be treated with a simple appendectomy or require complex oncological surgeries. Mucinous tumors are often associated with the presence of mucin or tumor implants in the abdominal cavity, being the clinical syndrome known as pseudomyxoma peritonei (PMP). PMP tends to present an indolent but deadly evolution and requires a multimodal approach as a single treatment with curative potential: complete cytoreductive surgery plus hyperthermic Intra-peritoneal chemotherapy (CCRS + HIPEC) now considered the standard of care in this pathology. The general surgeon should be aware of the governing principles of the treatment of appendiceal neoplasms with or without peritoneal dissemination, know the therapeutic frontiers in every situation (avoiding unnecessary or counterproductive surgeries) and sending early these patients to specialised centres in the radical management of malignant diseases of the peritoneum in the conditions and with the necessary information to facilitate a possible radical treatment.

Entities:  

Keywords:  Complete cytoreductive surgery (CCRS); Epithelial tumours of the appendix; Hyperthermic intra-peritoneal chemotheray (HIPEC); Mucinous appendiceal tumours; Mucinous dissemination from appendiceal neoplasm; Multimodality radical treatment of peritoneal carcinomatosis; Pseudomyxoma peritonei (PMP); Sugarbaker´s technique

Mesh:

Year:  2015        PMID: 26489426     DOI: 10.1007/s12094-015-1413-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  76 in total

1.  Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy.

Authors:  P H Sugarbaker; D Chang
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

Review 2.  Current status and future directions in appendiceal cancer with peritoneal dissemination.

Authors:  Konstantinos I Votanopoulos; Perry Shen; John H Stewart; Edward A Levine
Journal:  Surg Oncol Clin N Am       Date:  2012-10       Impact factor: 3.495

3.  Cytoreduction including total gastrectomy for pseudomyxoma peritonei.

Authors:  P H Sugarbaker
Journal:  Br J Surg       Date:  2002-02       Impact factor: 6.939

4.  How should we treat mucinous appendiceal neoplasm? By laparoscopy or laparotomy? A case report.

Authors:  G Liberale; Ph Lemaitre; D Noterman; C Moerman; E de Neubourg; N Sirtaine; I El Nakadi
Journal:  Acta Chir Belg       Date:  2010 Mar-Apr       Impact factor: 1.090

5.  Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases.

Authors:  Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

6.  Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding.

Authors:  S González-Moreno; P H Sugarbaker
Journal:  Br J Surg       Date:  2004-03       Impact factor: 6.939

7.  Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.

Authors:  Nicolas Golse; Naoual Bakrin; Guillaume Passot; Faheez Mohamed; Delphine Vaudoyer; François-Nöel Gilly; Olivier Glehen; Eddy Cotte
Journal:  J Surg Oncol       Date:  2012-02-13       Impact factor: 3.454

8.  Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.

Authors:  Paul H Sugarbaker; Robert Alderman; Gary Edwards; Christina Ellen Marquardt; Vadim Gushchin; Jesus Esquivel; David Chang
Journal:  Ann Surg Oncol       Date:  2006-03-10       Impact factor: 5.344

Review 9.  Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts.

Authors:  D Elias; B Detroz; B Debaene; E Damia; B Leclercq; P Rougier; P Lasser
Journal:  Hepatogastroenterology       Date:  1994-06

10.  Surgical treatment of appendiceal mucocele.

Authors:  Luca Stocchi; Bruce G Wolff; Dirk R Larson; Jeff R Harrington
Journal:  Arch Surg       Date:  2003-06
View more
  3 in total

1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

Authors:  V López-López; P A Cascales-Campos; E Gil; J Arevalo; A Gonzalez; J Gil; F C Muñoz-Casares; J T Melero; P Barrios; R Morales; I Ramos; G Ortega; B Camps; L González-Bayón; P Bretcha-Boix; J Farré-Alegre; S González-Moreno; P Parrilla
Journal:  Clin Transl Oncol       Date:  2017-08-10       Impact factor: 3.405

Review 2.  [Incidental finding of mucinous neoplasia of the appendix : Treatment strategies].

Authors:  F Köhler; M Rosenfeldt; N Matthes; C Kastner; C-T Germer; A Wiegering
Journal:  Chirurg       Date:  2019-03       Impact factor: 0.955

3.  Colorectal anastomosis during cytoreductive radical surgery in patients with peritoneal surface malignancies. Validation of a new technique (without stoma) to prevent anastomosis leakage in more than 1000 procedures.

Authors:  P Barrios; I Ramos; O Crusellas; D Sabia; S Mompart; M Martín-Baranera
Journal:  Clin Transl Oncol       Date:  2021-01-03       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.